Lightcalls.com
 

Finding the Honey & Growing the Biz...

Finding the Honey & Growing the Bizz ..CAs in Corporate Finance

Editor's Note: Several of the CAs featured in the following article and in the Feature Story forward page 10 were also interviewed for the ICABC newspaper postscript that appeared September 6 in The Vancouver light

"Corporate finance' is a make a humming sound phrase, and no one really knows what it means," says Vern Blair, CA, FCBV a partner with Vancouver's Blair Crosson Voyer "What are the rules? It's an imperfect market; it shifts constantly; and finding the right human frame or group to finance a concoct at the right time is repeatedly serendipitous-sometimes even just a matter of luck"

Until the entrepreneurial roller in the economy a small in number years ago, corporate finance wasn't on a level a practice area for CAs. While there's been a "correction" in the marketplace, helping clients find financing is still a actual important part of a CA practice.

"We'll probably not at all see the massive rush to market that we saw across the last few years, and the bulk of mankind will be a lot more selective about what they invest in," says Blair, "but that's part of our job-- to help the couple sides sort out the best solutions."



Along with lawyer Charlotte Bell of The Catalyst collection Blair will present a recently made known course offered by the Institute's Professional progressive growth program on November 19 at the Sutton Place inn entitled "A Practical Guide to Corporate Finance."

"Right now, tribe are scrambling to find coin to continue projects, but there's still a accident of money available for unmutilated businesses, especially in the areas of biotech, medicine, and pharmaceuticals," he points disclosed "The first thing I do with a of recent origin client is determine how frequently they need, thoroughly analyze their business, and then provide introductions to the appropriate hazard capitalists."

Contacts are everything, says Blair, and with a smaller market of financiers, it's difficult for entrepreneur to find the right fit.

"Spe is important as well because someone otherwise probably has the same idea, and if they master to market first, they may become the dominant player. Then it becomes on the same level harder to compete," he says. "Just direct the eye at Microsoft."

A 1966 graduate of the University of British Columbia's system of exchanges faculty, Blair articled with Arthur Andersen in Vancouver and became a CA in 1969 He complet his Certified Business Valuator designation in 1978 and was picked a Fellow of that organization in 1990 He'd been a partner specializing in business valuations with Deloitte's from 1969 to 1998 when he joined Blair Crosson Voyer

"The mostly important thing to have is a working knowledge of financing sources and markets," Blair says. "How we help clients can vary. For example, I had a just discovered client recently, and after taking a complete look at their business, I realized certain sections of the business were attractive to investors, if it were not that others were not. We sectioned the financing plan and almost immediately raise venture capital sources for the company."

Another important area of consideration is tax. "Tax implications have a cyclopean impact on the structure of corporate finance transactions," says Brad Gordica, CA, of Arthur Andersen LLP in Vancouver.

"I provide assistance to our Corporate Finance department because of my specialty in tax," Gordica explains. "That department began in Vancouver just from one side of to the other two years ago and has grown to five senior advisors with a wide range of large and mid-sized clients. They draw forward the depth of the stay of the firm and forward our global network as well. A destiny of success in this area is hanging on having the contacts and putting the right nation in touch with one another, whether that's across town or across continents."

A native of Alberta and a graduate of the University of Alberta, Gordica has been a CA since 1992 and lately became a partner at his firm. He says his CA designation, and particularly his focus in succession tax, have been very useful in creating forms to maximize value for clients.

"There is almost more demand for corporate finance advice today than there was during the furious hot high tech marketplace of a bond of years ago," Gordica says. "Now folks have had a chance to descry what can happen when you don't have righteous independent, objective advice and information. While that has created a more conservative marketplace, it's finally going in the right direction."

Gordica points abroad that technology has been an enormous generous to the speed and comprehensiveness of research that the firm is able to generate for clients. "Also, because of technology, clients are more sophisticated and thus more demanding," he says.

"I believe this is an area in which CAs will continue to have an animation because of the profession's capable reputation for independence and ethics," Gordica says.

Donna Bridgeman, MBA, CA, says her CA has been particularly useful in the areas of accounting policy, weighing a company's financial potency forecasting, and finance.

"My CA training, combined with my MBA, provides me with the wideranging skills I ne to assess investment opportunities as well as to assist 'investee' companies in developing their potential," she says.



Other Articles
 -Morphotek will collaborat...
 -Eksigent Technologies nam...
 -The benefits of outsourci...
 -Sartorius Corporation ...
 -In our previous column, w...
 -Efoora appointed Michael ...
 -Affymax appointed Anne-Ma...
 -Traditionally, continuous...
 -New Brunswick Scientific ...
 -The German-American firm ...
 -Don G. Burstyn, formerly ...
 -American patients are mor...
 -Summary Prior to va...
 -BioPharm Editorial Adviso...
 -Australia agreed to spend...
 -The Biotechnology Industr...
 -Ambion, The RNA Company i...
 -Therapies based on living...
 -A recent survey found tha...
 -ViroLogic will acquire Ac...
 -Cardinal Health named Joh...
 -One of the greatest chall...
 -As the president of a sma...
 -Sweden-based Biovitrum wi...
 -Nanogen appointed David L...
 -The Experion Process Know...
 -Although biomedical resea...
 -The Supreme Court of Cana...
 -Netherlands-based DSM Bio...
 -David A. Smoller joined S...
 -A few months ago, I wrote...
 -Panacos Pharmaceuticals w...
 -Karen K. Vaccaro will res...
 -Acceleron Pharma appointe...
 -Two quarterly meetings of...
 -Illinois-based Abbot Labo...
 -FKI Logistics announced t...
 -The following corrections...
 -It its widest definition,...
 -UK-based Xcellsyz will li...
 -Andrew P. Aromando joined...
 -Invitrogen's comprehensiv...
 -Last month, we described ...
 -The Swiss life sciences c...
 -Protein Design Labs (PDL)...
 -Model It HNMR, the newest...
 -Tech transfer, like chang...
 -QLT and Atrix Laboratorie...
 -Dendreon announced Christ...
 -Baxter Pharmaceutical Sol...
 -The biopharmaceutical ind...
 -GlaxoSmithKline announced...
 -Montreal-based Caprion Ph...
 -Xenova Group recently ann...
 -Cole-Parmer's new 192-pag...
 -Over the last decade ther...
 -Benchmark your facility p...
 -As biotechnology organiza...
 -Frederick D. Sancillo, fo...
 -Insmed acquired a recombi...
 -Baxter Pharmaceutical Sol...
 -Model It HNMR, the newest...
 -DA's regulation 21 CFR Pa...
 -Robert P. Ryan joined Ath...
 -A new report from Busines...
 -Biotest offers a complete...
 -Swagelok offers a brochur...
 -Partnering is a global ph...
 -Human Genome Sciences CEO...
 -Shorten the process devel...
 -The licensure of biotechn...
 -Rodger Currie joined Amge...
 -The GEA Filtration Model ...
 -A multi-channel chemistry...
 -From June 6-9, San Franci...
 -Skanska USA Building Inc....
 -New Brunswick Scientific'...
 -AVI BioPharma appointed P...
 -Ambion, The RNA Company, ...
 -"If you want to be a...
 -Xcellerex appointed Susan...
 -Researchers identified th...
 -Cool Spring Business Park...
 -In October 2003, Shenzhen...
 -Laureate Pharma appointed...
 -After a 6-5 vote by Calif...
 -QSourcing, a service of Q...
 -The recent discovery of &...
 -Affymax added Douglas L. ...
 -USDA recently approved tw...
 -BioPharm International is...
 -Serologicals has released...
 -This document by Shenzhen...
 -Robert Bronstein joined A...
 -Gloucester Gains Fujisawa...
 -With more than 30 years o...
 -Pall's SUPRAdisc II depth...
 -In today's competitive ma...
 -Protein Design Labs repor...
 -Charles A. Rice will repl...
 -AstraZeneca's Faslodex (f...
.
© 2006 Lightcalls.com All rights reserved.